Effects of noradrenergic lesions on the development of rolipram- sensitive, low-K(m), cyclic AMP specific phosphodiesterase in rat brain

Developmental Brain Research

Volumn 116, Issue 2, 1999, Pages 181-189

  Zhang, Kehong ^a   Farooqui, Shakeel M ^a   Jackson, Keasha T ^a   O'Donnell, James M ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

6 Hydroxydopamine; b Adrenergic receptor; Development; Phosphodiesterase

Indexed keywords

BETA ADRENERGIC RECEPTOR; CYCLIC AMP; OXIDOPAMINE; PHOSPHODIESTERASE; ROLIPRAM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN STEM; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL PROLIFERATION; ENZYME ACTIVITY; FEMALE; IMMUNOBLOTTING; NONHUMAN; NORADRENERGIC SYSTEM; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, NEWBORN; BRAIN; BRAIN STEM; CEREBELLUM; CEREBRAL CORTEX; CYCLIC AMP; KINETICS; MOLECULAR SEQUENCE DATA; OXIDOPAMINE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA; ROLIPRAM;

EID: 0032846168     PISSN: 01653806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-3806(99)00093-0     Document Type: Article

References (44)

1. Barad M., Bourtchouladze R., Winder D.G., Golan H., Kandel E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc. Natl. Acad. Sci. U.S.A. 95:1998;15020-15025.
2. Beavo J.A., Conti M., Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46:1994;399-405.
3. Bolger G.B., Erdogan S., Jones R.E., Loughney K., Scotland G., Hoffmann R., Wilkinson I., Farrell C., Houslay M.D. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem. J. 328:1997;539-548.
4. Chang Y.H., Conti M., Lee Y.C., Lai H.L., Ching Y.H., Chern Y. Activation of phosphodiesterase IV during desensitization of the A2a adenosine receptor-mediated cyclic AMP response in rat pheochromocytoma (PC12) cells. J. Neurochem. 69:1997;1300-1309.
5. Cherry J.A., Davis R.L. A mouse homolog of dunce, a gene important for learning and memory in Drosophila, is preferentially expressed in olfactory receptor neurons. J. Neurobiol. 28:1995;102-113.
6. Conti M., Iona S., Cuomo M., Swinnen J.V., Odeh J., Svoboda M.E. Characterization of a hormone-inducible, high affinity adenosine 3′-5′-cyclic monophosphate phosphodiesterase from rat Sertoli cell. Biochem. J. 34:1995;7979-7987.
7. Conti M., Swinnen J.V., Tsikalas K.E., Jin S.L. Structure and regulation of rat high-affinity cyclic AMP phosphodiesterases: a family of closely related enzymes. Adv. Second Messenger Phosphoprotein Res. 25:1992;87-99.
8. Conti M., Toscano M.V., Petrelli L., Geremia R., Stefanini M. Involvement of phosphodiesterase in the refractoriness of the Sertoli cell. Endocrinology. 113:1983;1845-1853.
9. Dauwalder B., Davis R.L. Conditional rescue of the dunce learning/memory and female fertility defects with Drosophila or rat transgenes. J. Neurosci. 15:1995;3490-3499.
10. + gene. Proc. Natl. Acad. Sci. U.S.A. 86:1989;3604-3608.
11. Della Fazia M.A., Servillo G., Sassone-Corsi P. Cyclic AMP signalling and cellular proliferation: regulation of CREB and CREM. FEBS Lett. 410:1997;22-24.
12. Dousa T.P. Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int. 55:1999;29-62.
13. N.R. Draper, H. Smith, Applied Regression Analysis, Wiley, New York, 1966.
14. Dudai Y., Jan Y.N., Byers D., Quinn W., Benzer S. Dunce, a mutant of Drosophila deficient in learning. Proc. Natl. Acad. Sci. U.S.A. 73:1976;1684-1688.
15. Egawa T., Mishima K., Matsumoto Y., Iwasaki K., Iwasaki K., Fujiwara M. Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairment of learning and memory in rats. Jpn. J. Pharmacol. 75:1997;275-281.
16. Engels P., Fichtel K., Lubert H. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. 350:1994;291-295.
17. Erdogan S., Houslay M.D. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Biochem. J. 321:1997;165-175.
18. Fleischhacker W.W., Hinterhuber H., Bauer H., Pflug B., Berner P., Simhandl C., Wolf R., Gerlach W., Jaklitsch H., Sastre-y-Hernandez M., Schmeding-Wiegel H., Sperner-Unterweger B., Voet B., Schubert H. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology. 26:1992;59-64.
19. Griebel G., Misslin R., Vogel E., Bourguignon J. Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors. Pharmacol. Biochem. Behav. 39:1991;321-323.
20. Hebenstreit G.F., Fellerer K., Fichte K., Fischer G., Geyer N., Meya U., Sastre-y-Hernandez M., Schony W., Schratzer M., Soukop W., Trampitsch E., Varosanec S., Zawada E., Zochling R. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry. 22:1989;156-160.
21. Iona S., Cuomo M., Bushnik T., Naro F., Sette C., Hess M., Shelton E.R., Conti M. Characterization of rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain. Mol. Pharmacol. 53:1998;23-32.
22. B2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions. Biochem. J. 304:1994;399-406.
23. McPhee I., Pooley L., Lobban M., Bolger G., Houslay M.D. Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. Biochem. J. 310:1995;965-974.
24. Nicholson C.D., Jackman S.A., Wilke R. The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site. Br. J. Pharmacol. 97:1989;889-897.
25. O'Donnell J.M. Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J. Pharmacol. Exp. Ther. 264:1993;1168-1178.
26. Pittman R.N., Minneman K.P., Molinoff P.B. Ontogeny of β-1 and β-2 adrenergic receptors in rat cerebellum and cerebral cortex. Brain Res. 188:1980;357-368.
27. Rainbow T.C., Parsons B., Wolfe B.B. Quantitative autoradiography of β-1 and β-2 adrenergic receptors in rat brain. Proc. Natl. Acad. Sci. U.S.A. 81:1984;1585-1589.
28. Sachs C., Jonsson G. Effects of 6-hydroxydopamine on central noradrenaline neurons during ontogeny. Brain Res. 99:1975;277-291.
29. Seybold J., Newton R., Wright L., Finney P.A., Suttorp N., Barnes P.J., Adcock I.M., Giembycz M.A. Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by8-bromo-cAMP and Gs-coupled receptor agonists: potential role in beta2-adrenoreceptor desensitization. J. Biol. Chem. 273:1998;20575-20588.
30. Shellenberger M.K., Gordon J.H. A rapid, simplified procedure for simultaneous assay of norepinephrine, dopamine, and 5-hydroxytryptamine from discrete brain areas. Anal. Biochem. 39:1971;356-372.
31. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85.
32. Sutor B., Mantell K., Bacher B. Evidence for the activity of five adenosine-3′,5′-monophosphate-degrading phosphodiesterase isozymes in the adult cerebral cortex. Neurosci. Lett. 252:1998;57-60.
33. Swinnen J.V., Joseph D.R., Conti M. Molecular cloning of rat homologues of Drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes. Proc. Natl. Acad. Sci. U.S.A. 86:1989;5325-5329.
34. Swinnen J.V., Tsikalas K.E., Conti M. Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat Sertoli cell. J. Biol. Chem. 266:1991;18370-18377.
35. Takahashi M., Terwillinger R., Lane C., Mezes P.S., Conti M., Duman R.S. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J. Neurosci. 19:1999;610-618.
36. 125I -iodopindolol J. Pharmacol. Exp. Ther. 235:1985;1-9.
37. Torphy T.J., Cieslinski L.B. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Mol. Pharmacol. 37:1990;206-214.
38. 2. Implications for the therapeutic use of beta-adrenergic agonists. J. Biol. Chem. 270:1995;23598-23604.
39. Tully T., Quinn W.G. Classical conditioning and retention in normal and mutant Drosophila melanogaster. J. Neurogenet. 9:1985;55-71.
40. Wachtel H., Schneider H.H. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology. 25:1986;1119-1126.
41. Wang P., Myers J.G., Wu P., Cheewatrakoolpong B., Egan R.W., Billah M.M. Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. Biochem. Biophy. Res. Commun. 234:1997;320-324.
42. Ye Y., O'Donnell J.M. Diminished noradrenergic stimulation reduces the activity of rolipram-sensitive, high affinity cyclic AMP phosphodiesterase in rat cerebral cortex. J. Neurochem. 66:1996;1894-1902.
43. Ye Y., Conti M., Houslay M.D., Farooqui S.M., Chen M., O'Donnell J.M. Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain. J. Neurochem. 69:1997;2397-2404.
44. m, cyclic AMP specific phosphodiesterase in rat brain. Dev. Brain Res. 112:1999;11-19.